Tempus AI is trading at $52.03 (-4.16%), with the specific catalyst unclear.

  • No clear company-specific announcement or analyst action surfaced for August 14, 2026.
  • Recent positive FDA xT approval coverage and second-quarter results do not explain today’s decline.
  • Software stocks are rising, while major indexes are modestly lower; Personalis acquisition dilution concerns remain a potential overhang from its July 20 announcement.